PMcardio

by Powerful Medical  · Based in Slovakia → — AI that reads ECGs in seconds
Cardiology Emergency Medicine Internal Medicine
Website
Claim this tool
Is this the maker? Claim the company →

Freemium
Regulatory Status Disclosed

Overview

PMcardio, developed by Powerful Medical, is an AI-powered clinical assistant designed to digitize and interpret 12-lead electrocardiograms (ECGs). The platform is built for emergency physicians, general practitioners, cardiologists, paramedics, and nurses across diverse care settings, including emergency departments, ambulances, clinics, and hospital wards.

The tool integrates into clinical workflows by allowing providers to capture an image of any paper-based or digital 12-lead ECG using a smartphone. PMcardio’s AI models then analyze the image to detect over 50 distinct ECG findings, including arrhythmias, conduction blocks, and structural changes.

Notable Capabilities:

  • STEMI and OMI Detection: The “Queen of Hearts” model identifies acute ST-elevation myocardial infarctions (STEMI) and occlusive myocardial infarctions (OMI).
  • LVEF Screening: The “LVsense” model screens for reduced left ventricular ejection fraction (LVEF) directly from a standard ECG.
  • Explainability Heatmaps: The “ECGxplain” feature visually highlights the specific leads and segments influencing the AI’s diagnostic predictions.
  • Regulatory Status: PMcardio is certified as a Class IIb medical device under the EU Medical Device Regulation (MDR) and is registered with the UK MHRA. It has received FDA Breakthrough Device Designation for its STEMI AI model but is not yet cleared for marketing in the United States.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Instant AI-powered ECG interpretations
  • Detection of 50+ ECG findings (including STEMI/OMI, rhythms, reduced LVEF, conduction disorders)
  • Queen of Heartsu2122 - STEMI and OMI Detection
  • LVsenseu2122 - Reduced LVEF Detection
  • ECGxplainu2122 - Visual AI Explainability with heatmaps
  • Core AI - Detects 36 core diagnoses (arrhythmias, conduction blocks, heart blocks, chamber hypertrophies)
  • Automatic analysis of heart rate, axis, P wave, PR, QRS, and QT/QTc intervals
  • Culprit Artery AI confidence scores with 3D heart visualization
  • AI Confidence Scores for clinical decision-making
  • Digitize and share ECG reports

Use Cases

  • Rapid diagnosis at first patient contact
  • Early detection of reduced Left Ventricular Ejection Fraction (LVEF)
  • Detection of acute ST-elevation myocardial Infarction (STEMI) and STEMI-equivalent patterns
  • Screening for structural heart disease
  • Longitudinal monitoring of cardiac conditions
  • Streamlining patient management and referral to cardiovascular specialists

What Physicians Need to Know

ECG/EKG Analysis Capability
PMcardio offers CE-certified AI ECG Models that provide a complex assessment of over 50 ECG findings, including rhythms, arrhythmias, conduction disorders, ischemia, and infarction. It can digitize any 12-lead ECG (paper or screen) into a standardized digital waveform, even improving the quality of old or distorted ECGs. The AI provides instant interpretation, reducing the average diagnosis time to 2.1-2.5 seconds.
Echocardiography AI Features
PMcardio's Echo Screening Suite offers AI-powered screening for structural heart disease directly from a 12-lead ECG, detecting conditions such as reduced Left Ventricular Ejection Fraction (LVEF), aortic stenosis, and hypertrophic cardiomyopathy (HCM). The LVEF AI ECG model has demonstrated high performance (AUC 0.963) in detecting reduced heart function.
Cardiac CT/MRI Analysis
PMcardio's Angio Suite provides AI-powered analysis of coronary angiography, including automated stenosis quantification, TIMI frame count, guide wire detection, and myocardial blush grading in near real-time.
Arrhythmia Detection Accuracy
PMcardio identifies atrial fibrillation (and other arrhythmias) with 98.3% accuracy, comparable to board-certified cardiologists. In a study of COVID-19 patients, PMcardio achieved perfect diagnostic accuracy (sensitivity and specificity of 1.00) for AF detection.
Heart Failure Risk Prediction
PMcardio includes an AI-driven platform for predictive analysis of heart failure, leveraging machine-learning techniques to analyze ECGs for early diagnosis and management recommendations. The PM-Aalst heart failure mortality prediction system, developed in partnership with the Cardiovascular Center Aalst, has shown superior performance in predicting short and long-term mortality across various heart failure phenotypes.
Coronary Artery Assessment
The 'Queen of Hearts' (OMI AI Model) enables detection of Occlusion Myocardial Infarction (OMI) from any 12-lead ECG, even without typical ST elevation, and has received FDA Breakthrough Device Designation. It has demonstrated 2x higher sensitivity than traditional criteria for STEMI detection and can reduce false STEMI alarms by over 60%.
Cardiac Monitoring Integration
PMcardio offers a Remote Monitoring Suite for AI-powered analysis of ambulatory ECG recordings from Holter monitors, cardiac patches, and other continuous monitoring devices, providing automated findings and longitudinal tracking. It also has a Patient Suite for AI-powered ECG interpretation from consumer wearables.
AHA/ACC Guideline Alignment
PMcardio's treatment recommendations engine is built using decision trees constructed from official clinical practice guidelines published by the European Society of Cardiology (ESC). The platform aims to help meet the crucial 90-minute window from first medical contact as recommended by ACC/ESC/AHA guidelines for STEMI.
Real-Time Alert Capability
PMcardio provides real-time alerts and care routing, with instant notifications when a critical finding is detected and built-in escalation to the appropriate team member. This functionality enhances communication and accelerates care delivery.
Physician Tip

PMcardio can significantly enhance diagnostic confidence and efficiency, especially in acute care settings and primary care, by providing rapid, AI-powered ECG interpretations and guideline-adherent treatment recommendations. Its ability to detect subtle STEMI equivalents and reduced LVEF from ECGs can lead to earlier intervention and improved patient outcomes. For institutions, the platform offers integrated care coordination and real-time alerting, streamlining workflows and reducing false activations. While highly accurate for many conditions, be aware that its performance for signs of past or present ischemia might be more modest, and local calibration and prospective multicenter validation are important for widespread clinical implementation.

PMcardio is designed for enterprise-ready deployment, connecting to existing ECG devices, EHR/CVIS, EMS systems, angiographic systems, and communication tools. It supports seamless integration across hospital networks with a single integration, contract, and security review. The platform can be launched from the EHR with secure links and SSO, and it sends results back to clinical systems for documentation. PMcardio has also partnered with Roche to integrate AI-powered ECG interpretation into the cobasu00ae pulse point-of-care platform.

Details

Category Cardiology AI, Clinical Decision Support & Reference
Pricing Freemium
DeploymentMobile app (iOS and Android), Web platform, Enterprise integrations with EHR/CVIS and EMS systems
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Pending AI-estimated
Integrations
EHR Not specified
Specialties Cardiology, Emergency Medicine, Internal Medicine

What the Web Says

PMcardio is an AI-powered platform designed for ECG digitization, analysis, and treatment of cardiovascular diseases, primarily aimed at medical professionals. It has been clinically validated in numerous studies, demonstrating high accuracy in detecting various cardiac conditions, including atrial fibrillation and subtle STEMI equivalents. While generally well-received by physicians as a valuable diagnostic aid, some concerns exist regarding its FDA approval status in the US and occasional inaccuracies.

Overall: Positive

Strengths

  • High accuracy in detecting major ECG abnormalities and atrial fibrillation.
  • Outperforms general cardiologists and primary care doctors in some ECG interpretations.
  • Aids in rapid diagnosis, especially in emergency situations.
  • Can identify subtle or occlusion MI patterns that might be missed by human interpretation.
  • Provides guideline-based treatment recommendations.
  • User-friendly interface and ability to digitize ECGs from any device by taking a photo.

Limitations

  • Not yet FDA cleared for clinical decision-making in the US, though it has FDA Breakthrough Device Designation.
  • Some users reported inaccuracies, including missed STEMIs and incorrect diagnoses.
  • Limited usage in the free version and a paid subscription is required for unlimited access and advanced features.
  • Not designed for interpretation of Apple Watch ECGs or other consumer-facing devices.
  • Some skepticism among cardiologists regarding its implementation and the OMI paradigm.
  • Not available in all regions, with some US users experiencing restrictions.

Based on reviews from: Reddit, App Store - Apple, GetApp UK, YouTube, PMC, Powerful Medical, HealthUnlocked, G2, Capterra

Last updated: 2026-09-30

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate PMcardio

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for PMcardio.

View all on YouTube

Frequently Asked Questions

PMcardio employs AI algorithms to analyze ECGs, identifying patterns and anomalies that may be indicative of various cardiac conditions. This AI-powered interpretation aims to augment, not replace, physician analysis, potentially improving diagnostic speed and consistency, especially in high-volume settings or for less common presentations.
PMcardio is a CE-marked medical device under the Medical Device Regulation (MDR), signifying its compliance with European safety and performance requirements. It also adheres to stringent data privacy regulations like GDPR, ensuring patient data is handled securely and confidentially.
While several AI-powered ECG analysis tools are emerging, PMcardio differentiates itself through its comprehensive diagnostic capabilities, covering a wide range of cardiovascular diseases. It also emphasizes seamless integration with existing EHR systems, aiming to minimize disruption to clinical workflows.
PMcardio offers various pricing models, including subscription-based options, tailored to the needs of both individual practitioners and larger healthcare institutions. Specific details on pricing tiers and packages are typically provided upon direct inquiry to accommodate diverse operational scales and requirements.
While highly accurate, PMcardio's AI, like all AI, has limitations. Its performance might vary with extremely rare conditions or severely artifact-laden ECGs. The system is continuously updated and refined to improve its accuracy across diverse scenarios and patient populations, with ongoing research addressing these limitations.
PMcardio prioritizes data security and patient confidentiality through robust encryption protocols and adherence to international data protection regulations like GDPR. All data transmission and storage are secured to prevent unauthorized access and ensure compliance with healthcare privacy standards.
PMcardio provides comprehensive training and ongoing support for physicians to ensure effective utilization of the platform. This includes educational resources, user guides, and direct support channels to help clinicians integrate AI-generated insights with their clinical expertise for optimal patient care.

Compare PMcardio

VS
Study Watch vs PMcardio
Cardiology AI Adjacent · 65/100
Verily Study Watch is a wearable device primarily designed for continuous physiological monitoring in clinical research, collecting various data points including ECG, heart rate, and movement for analysis…
VS
EchoGo Pro vs PMcardio
Cardiology AI Adjacent · 65/100
Both Ultromics' EchoGo Pro and Powerful Medical's PMcardio are AI-powered cardiology tools, but they focus on different diagnostic modalities. EchoGo Pro specializes in automating stress echocardiography analysis for…
VS
uOmnispace.MI vs PMcardio
Cardiology AI Adjacent · 60/100
uOmnispace.MI is an advanced medical imaging software for comprehensive analysis of various modalities like PET, CT, MR, and SPECT images, supporting oncology, neurology, and cardiology workflows. PMcardio, on…
VS
uOmnispace.MR vs PMcardio
Cardiology AI Adjacent · 60/100
uOmnispace.MR and PMcardio are adjacent tools in the cardiology AI space, both aiding in cardiac diagnostics. uOmnispace.MR focuses on advanced post-processing and AI-driven segmentation of MR images for…

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-07-01 | First Added: 2026-07-01

Investors who backed PMcardio

Funded through the company that built this tool.

LifeX Ventures
VC T3
New York, United States
$1M-$5M
LifeX Ventures positions as a longevity and human-performance focused investor, backing companies at the intersection of biology, consumer health, and software. With…
AI/ML in Healthcare Biotech
AI Tool Finder
AI-powered search. Results may not be comprehensive.